investor
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I think 100milliondollars might be referring to the fact that about 6 months ago INO's market cap was over $900 million dollars, and as of today, their market cap is under $600 million dollars.
Of course this occurred after dilution and the R/S. I hope ONCS does not follow the same path.
I agree with Geert, now is a excellent buying opportunity.
Great results with RXI-109 at one month and better results expected in the coming months.
Excellent science and discovery will lead to partnership opportunities and an excellent pipeline, for the long term.
12% bump today, No news yet.
Anybody?
PPS holding near the 20 day moving average.
No news to move this forward. Loading up for future results.
Starcig,
Thanks for the confirmation of the possible retracement to $.54.
I have buy orders in at $.59 and $.55, after a sale today at a resistance level of $.64. PPS share may not get there, but I make my decisions and live with them, even if doesn't play well with some on the board.
I guess that's why we have the ignore feature available on ihub. For those posters that you feel add nothing relevant to your DD, I strongly recommend this feature.
GLTA the longs, hope the rest of 2014 is as profitable as we hope.
RXII pps is up 60% from the intra-day bottom of a few months ago.
Current pps of $3.60, with analysts targets between $8 and $13.50 pps.
Looking good to move much high on positive news!
PPS up 17.75% last week.
PPS up 11.41% Today.
Probably not going to go straight up from here, but nice move over the last 6 days.
Any more predictions on the PPS or the direction of this "piece of success"?
Busted through the 76,000 share ask of $3.00.
Onward and Upward!
Nice week for RXII, up almost 18%.
Just the start of a very positive last 4 months of 2014.
TFOM,
I, like you probably, was sold on the technology and the unmet medical need in the treatment of SCI.
The logistics of getting the technology into human trials, I believe as a little more than Frank Reynolds was capable of.
To raise money to fund the human trial the pps was dropped from $2.00 to $1.15, not what attracts new or current shareholder to buy and hold. Now we sit at a pps of $.60. I have bought some shares on the way down, but recent management statements: the pps will remain under pressure until the human trial begins and we starting getting data, have not helped the pps.
Do I think this is a great opportunity to get in on this speculative company? I do, but even though I see a decent amount of volume, it hasn't seem to support the pps to this point.
New management has tried to design a trial to get the scaffolding used in a human trial, but I feel the design may limit the number and type of patients that can be enrolled in the trial.
We have waited almost 4 months for the first patient to be enrolled and I will probably continue to try and be patient.
If the technology is tested and provides benefit to patients with SCI, there may yet be a win in this for both the patients and the investors.
Good luck to all, and I hope our patience pays off,
Nice move up recently.
Have a hard time breaking the $3.00 barrier.
Currently 76,000 shares on the ask at $3.00.
Good call.
NovaBay Pharmaceuticals (NBY_) plummeted to a 52-week low of 69 cents on Wednesday after the company announced its potential adenoviral conjunctivitis treatment did not meet its primary or secondary endpoints in a Phase 2 clinical study.
RXi Pharmaceuticals Corporation (RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that the Company will ring the NASDAQ Stock Market closing bell on Friday, August 8, 2014.
"Listing on NASDAQ has allowed us to gain access to a broader institutional investment community," said Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals. He added that, "Commemorating this accomplishment, by ringing the NASDAQ closing bell, is a good reminder of the progress we have already achieved with developing our self-delivering RNAi-based (sd-rxRNA®) technology platform into commercially viable assets. We would like to thank our shareholders, patients, volunteers and advisors for their support in the Company's development."
Please post a link, I'd like to read it too.
As most people on this board know, there are links between ONCS and INO.
I think the link that many hope happens is:
Nov.12, 2012 INO pps was around $.46 pre-reverse split
August 5, 2013 INO pps was at $3.00 pre-reverse split.
I know most of us hope ONCS surpasses $3 pps, but I won't mind that price as a base to move higher.
Thank you for your in-depth analysis.
Your posts show the hours you've spent doing DD, with each one packed full of priceless information.
I agree with you assessment of where INO is as a company and the outlook for the near future.
Evidently, Dr Kim has everything in place (shelf) to initiate VGX-3100 phase 3 trial, which will keep him busy for the next 4-7 years while he tries to gain FDA approval. I guess with his recent investment in INO, Dr. Kim is willing to wait for his big payoff.
We will see if current and new investors are willing to wait that long. As far as catalysts we know nothing about, either Dr. Kim is very good at keeping secrets, or INO timelines for any big news are now longterm.
No News.
No Support for the pps.
Where is the bottom?
Do you think the pps action over the last 3 months has anything to do with the whining and complaining?
We have many that try to explain this pps action, but the market is the reality and at this point ONCS sits at $.40.
I think one thing both companies have in common is the fact that both CEO's have chosen to announce dilution immediately after the release of positive news.
Of course this has had a negative impact on the PPS and I have still yet to find a reason for their timing of such announcements.
"Primary point we are looking for once the first patient is enrolled (which isn't a question of if but when) is the safety of the device."
Yes, the question is WHEN will the trial start.
Dr. Kim got the shares at a good price: $9.05
I believe investors might have been looking for the release of additional clinical information and/or information regarding a partnership to develop VGX-3100.
Dr. Kim only mentioned partnership in passing at the end of the presentation, but reaffirmed that INO has the funding to do the phase 3 trial on their own. Are his statements part of a negotiation strategy or:
The following was taken from my post after the phase 2 data:
Dr. Kim has made no secret that his primary focus is getting VGX-3100 into a phase 3 trial and I think he has a preference to run the trial without a partner. He wants to retain complete control. I believe doing the clinical trial without a partner brings undo risk to INO and the stock. Even the very largest pharma companies often partner to reduce the risk of phase 3 trials and potential market approval.
Still long, but hoping Dr. Kim and the board make the best decision with regard to partnering.
Not a good day for INO or ONCS.
Great technology, but no retail or institutional support today.
OK, I'll start.
Bought shares at $8.89 and $8.83
WOW!
So far the market is not impressed by INO's webcast.
Appreciate your post, Everywhereman.
Great information and I appreciate you willingness to give you honest assessment of the HPV trial, products, and the paths INO might take moving forward.
Re: Tomorrow
Good news, Bad news, No news?
INO over $10 pps or under at the close?
Some have suggested positives from the conference call, but how will that effect the pps?
Not too good on my predictions lately. I called for $14-$15 pps after the phase 2 news.
8/11/2014 close: $10.45
I have no specific commentary on Punit or the PR department.
I continue to invest in a company, even during the down times, if my DD has me confident in: the science, the management, or both. Over time my evaluation can change my perspective of the science and the management. PPS movement is an additional factor.
Because most people invest in a stock like ONCS to make money, rightly or wrongly (I think rightly), management is judged by how their stock performs.
While I am not as heavily invested in ONCS as some others on the board, I do believe that ONCS has a good chance of increasing the value of the company. I am holding my shares and feel that share price will rise following the attainment of the upcoming milestones.
I would like the pps to soar well above $1.50, but give recent pps movement, I will be satisfied with $1.50 as a starting point.
Yes, let's go back to the beginning of this 3 year old company.
How far it has come in 3 years and how much potential that hopefully is about to be realized.
I will state that Punit is one of the best biotech CEO's, if he can return the pps back to what is was 3 years ago: $1.50. I think he and his staff can do it, therefore I am holding my shares long for at least that moment.
Fair enough?
Gotta be a positive, that NAVB pps was able to shake off the "Sheff selloff" to move back to the $1.30 level.
165k shares purchased at the close and after hours.
Over 100k purchase at $1.45, $.07 over the price at the close.
See previous post as being possibly one of the reasons.
Look's like the pps has gone into a slow creep lower prior to the financial results announcement, on Monday.
Looking for buying opportunities today or Monday.
In the process of hopefully taking down 100k+ wall at $1.26.
HEPLISAV-B phase 3 trial moving forward
DV1179 treatment for Lupus did not meet primary or secondary endpoints in phase 1b/2a trial.
AZD1419 meets primary and secondary endpoints in phase 1 trial to treat asthma.
I will continue to look for opportunities to add to my investment, as I feel that while other pipeline products add value to Dynavax, Heplisav-B will be the driver of pps over the next few years.
Question:
Why do the managements(there are many) of biotech companies give the shorts and the manipulators ammunition to play their games?
It doesn't have to be in the form of R/S, dilution, or shelf registrations. It can be as simple as lack of communication by management to their shareholders.
Agreed, management needs to think long-term, for the most part, but with a little foresight, I believe management could often avoid the 30%+ drops in share price.
As far as DD, it is only as good as the information that is know to the public. Investors will never know all the plans and decisions management will make. So despite the best DD, investors are at the mercy of management.
PPS bounce off $.75 to $.82-$.84 range this A.M.
Was looking for news. Can't find any yet.
Each person must determine his own style of investing. I am not against the long term buy and hold type investing, but the pattern with INO over the last year has been very predictable.
When INO shares experience a run, they have almost always retreated back at least to the level of where the run started. This is not my opinion, this is factual, based on historical pps.
True, I did not agree with the R/S and the timing of the announcement of the shelf registration. Both, in my opinion had a negative effect on pps (selling). Whether you care about the day to day pps of INO, some shareholders do and they make buy and sell decision according to pps movement. Eventually you will need more buyers than sellers to move the pps higher, so the more interest in INO stock by investors the better for all the shareholders.
Dr. Kim could be the most brilliant scientist and businessman on the planet, but I tend to judge people by their actions and not what they know or their reputation.
Dr. Kim is running a company and part of running a company is selling that company to the public and institutions. Communication of the rationale for decisions he makes goes a long way to keeping investors informed and content.
Dr. Kim has made no secret that his primary focus is getting VGX-3100 into a phase 3 trial and I think he has a preference to run the trial without a partner. He wants to retain complete control. I believe this is a very risky move on his part, but it's all lined up now after phase 2 results and the almost instantaneous shelf registration. I'll be watching to see if Dr. Kim turns out to be both the scientist and businessman you think he is.
By the way, my preference for being rewarded might look more like a set of stairs for the pps not the path of a rollercoaster.
Okay PMGtrader,
Let's start an intelligent conversation.
1. Anyone is entitled to express an opinion on this board as long as you abide by the Terms of Service.
2. You are entitled to comment on those opinions, as long as you abide by the Terms of Service.
3. Legitimate opinions have been offered as to why INO pps can not hold gains after positive news. As has been outline this type of price action has become a pattern (this has happen 6 times in the last year) with INO pps. People tend to play patterns of price action until the pps no longer fits the pattern. Shorts and flippers continue to make money on this type of price action, while the longs watch their investment rollercoaster up and down. This current timeframe, 7/23-7/31, INO pps is down 36% from the 7/23 intraday high.
4. I have flipped a few hundred thousand shares of INO and have made good money, but at some point, INO should be able to hold gains and build to a higher pps. I stand by my statement "The best way to make money currently on INO is to flip shares". Until this rollercoaster pattern is broken by investors that see the long term value in holding shares long, for the long term, I think we will continue to see the pattern.
I think some people would like to have this board be a place where the INO cheerleaders can talk about how great everything is. Stockholders have a right to ask questions about companies they invest their money in, whether management cares about the opinions of their shareholders or not, these opinions often get reflected in the pps.
I hope Dr. Kim gets his wish and INO changes the way ID and cancer are treated. Unless it is profitable to invest in INO, he may lose some of those that want to be part owners in this potentially great company.
So where does this stop?
$.42?
Lower?
Ideas?